Several gut peptides and neuropeptides drive colorectal cancer growth, and antagonistic peptide analogs targeting these pathways show experimental promise alongside established VEGF and EGFR therapies.
Multiple peptide targetsGastrin, GRP/bombesin, IGF, and GHRH all implicated in colorectal cancer growth with experimental antagonists in development
What the researchers found
The review identifies multiple peptide systems involved in colorectal cancer growth:
- Gastrin and gastrin-releasing peptide (GRP/bombesin) promote CRC growth
- Insulin-like growth factor I and II are implicated in CRC progression
- Growth hormone-releasing hormone (GHRH) contributes to tumor growth
Experimental approaches include antagonistic analogs of bombesin/GRP, GHRH antagonists, and cytotoxic peptides that target peptide receptors on tumors to deliver chemotherapy directly to cancer cells. These peptide-based strategies complement existing VEGF and EGFR-targeting therapies.
Why it matters
Most patients with metastatic colorectal cancer eventually develop resistance to current therapies. Peptide-based approaches targeting tumor growth signaling through different pathways could provide new treatment options. Cytotoxic peptides that deliver drugs specifically to tumor cells via peptide receptors are particularly promising for reducing side effects.
How the study worked
This is a narrative review published in the World Journal of Gastroenterology, summarizing clinical data on established VEGF and EGFR-targeting regimens and preclinical/experimental data on peptide-based targeted approaches for metastatic colorectal cancer.
What this study cannot tell us
Published in 2014, many of the peptide-based approaches discussed were still experimental at the time. The review mixes well-established clinical data (VEGF/EGFR targeting) with early-stage preclinical peptide research. Clinical trial results for the peptide approaches were limited or absent at the time of publication.
How to read the evidence
This is a narrative review combining well-established clinical evidence for VEGF/EGFR targeting with largely preclinical or early-stage evidence for peptide-based approaches. The peptide therapy section relies primarily on experimental investigations.
When this study was published
Published in 2014, this review is now over a decade old. The VEGF/EGFR clinical data remains relevant, but the peptide-based approaches have evolved since publication. Readers should look for more recent updates on peptide cancer therapies.
The bigger picture
Peptide receptors are overexpressed on many cancer types, making them natural drug delivery targets. The concept of cytotoxic peptides — where a tumor-homing peptide carries a chemotherapy payload — is a peptide-based equivalent of antibody-drug conjugates. As our understanding of tumor peptide biology grows, so does the potential for precision peptide oncology.
Questions still open
- Have any of the peptide-based approaches discussed progressed to clinical trials for colorectal cancer since 2014?
- Could GHRH antagonists be combined with existing targeted therapies to overcome resistance?
- How do cytotoxic peptide conjugates compare in efficacy to antibody-drug conjugates for colorectal cancer?
Common questions
What are cytotoxic peptides for cancer treatment?
Why do gut peptides matter in colorectal cancer?
Read the original research
Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.
World journal of gastroenterology, 20(20), 6102-12
Citation
Hohla, Florian; Winder, Thomas; Greil, Richard; Rick, Ferenc G; Block, Norman L; Schally, Andrew V. (2014). Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.. World journal of gastroenterology, 20(20), 6102-12. https://doi.org/10.3748/wjg.v20.i20.6102